article
Empty phage viruses as a method to combat influenza
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
List view / Grid view
Bacteriophages
news
Novel phage display technique could lead to new peptide-based therapeutics
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
news
CRISPR-Cas3 used to combat C. difficile in lab and mice
Researchers have shown that CRISPR-Cas3 can successfully attack C. difficile in vitro and in mice, by causing DNA damage to the pathogen.
news
Phage-enriched mucosal surfaces could combat bacteria infections
Researchers have found that, in rainbow trout models, phages on mucosal surfaces infect pathogenic bacteria, providing protection.
news
Phage therapy shows potential to treat alcoholic liver disease
Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
news
Study identifies strain of bacteria as a risk factor for stomach cancer
Researchers have found a specific strain of Helicobacter pylori strongly correlated with stomach cancer...
news
Genetically engineered bacteria show promise as a new treatment for constipation
Researchers have genetically engineered bacteria as a potential new treatment for constipation, the finding is significant in part because there are few approved constipation remedies on the market...
news
Potential targets for treatment of leishmaniasis identified
Brazilian scientists show that parasite's penetration of host cells increases expression of certain microRNAs capable of inhibiting the action of the immune system...
news
University of Leicester gets funding to develop bacteriophages
27 May 2016 | By Victoria White, Digital Content Producer
Professor Martha Clokie has been awarded funding to develop bacteriophages to target bacterial infant diarrhoea in the developing world...
news
Pherecydes Pharma appoints Fanneau de La Horie as CEO
22 February 2016 | By Katie Sadler
Pherecydes Pharma has announced the appointment of Guy-Charles Fanneau de La Horie, MBA as its new Chief Executive Officer.
news
TAxI holds promise as a carrier for spinal cord treatments
17 February 2016 | By Victoria White
The small peptide has been shown to be an effective at shuttling functional proteins into the spinal cord after a muscle injection...
news
AmpliPhi appoints new VP of Chemisty, Manufacturing & Control
3 September 2015 | By Victoria White
AmpliPhi Biosciences Corporation has announced that Alexander Gaidamaka has been appointed as the new Vice President of Chemistry, Manufacturing and Control...
news
AmpliPhi Biosciences announce financial results Q2 2015
14 August 2015 | By Katie Sadler, Digital Content Producer, Drug Target Review
Biotechnology company, AmpliPhi Biosciences Corporation, released financial results for the second quarter 2015 and operational highlights. AmpliPhi, one of the leaders in the development of bacteriophage-based antibacterial therapies to treat antibiotic-resistant infections, has reported strong overall performance in overall liquidity and balance sheet strength thanks to a $13 million investment…
news
AmpliPhi’s bacteriophage manufacturing facility receives cGMP certification
4 June 2015 | By Victoria White
AmpliPhi's production facility in Ljubljana has been cleared by JAZMP to manufacture bacteriophages under current Good Manufacturing Practices standards...
news
Ferring and the Institut Pasteur collaborate in novel IDB drug development project
16 April 2015 | By Victoria White
Ferring and Institut Pasteur are collaborating aimed at identifying and developing bacteriophages to treat patients with inflammatory bowel disease (IDB)...